BranchLab, an AI platform focused on pharmaceutical commercialization, has successfully secured $26 million in Series A funding, increasing its total funding to $35 million.
This funding round was led by McKesson Ventures, which is known for investing in healthcare technology aimed at enhancing the efficiency and quality of healthcare delivery. Other notable investors included FCA Venture Partners, Sanofi Ventures, and AIX Ventures, indicating a strong interest in innovative solutions within the life sciences sector.
BranchLab plans to allocate the new funds towards expanding its enterprise deployments and enhancing integrations within the healthcare and media ecosystem. The company's AI-driven platform is designed to facilitate connections between patients, providers, and caregivers, thereby optimizing the commercialization of pharmaceutical products. By leveraging privacy-safe AI models, BranchLab aims to assist pharmaceutical organizations in effectively identifying target audiences and measuring campaign outcomes in real time.
This funding marks a significant step for BranchLab as it seeks to transform healthcare decision-making through the application of advanced AI technologies. The involvement of established investors in the healthcare space underscores the growing recognition of AI's potential to innovate and improve pharmaceutical commercialization processes.